Company: INTS
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001567264-25-000077
Chunk: 55

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 55
---
 research and development costs$849 $374 Accrued employee compensation-related expenses43 56 Accrued other49 78 Total$941 $508 

Note 7.    Stockholders’ Equity 

At The Market Offering AgreementOn July 3, 2024, the Company entered into an At The Market Offering Agreement (the “ATM Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may sell and issue, from time to time, up to $15.0 million of shares of its common stock (the “Shares”) through Wainwright as the Company’s sales agent (the “ATM Offering”). The Company has no obligation to sell any of the Shares and may at any time suspend offers under the ATM Sales Agreement or terminate the ATM Sales Agreement pursuant to its terms. On June 18, 2025, the Company filed a prospectus supplement to adjust the maximum the Company may sell and issue under the ATM Sales Agreement to $9.65 million of its Shares (“ATM Adjustment”), not including the Shares previously sold under the ATM Sales Agreement. Since inception through the ATM Adjustment, the Company had issued 193,816 shares of common stock under the ATM Sales Agreement for net proceeds of $0.5 million. For both the three and six months ended June 30, 2025, the Company issued 141,996 shares of common stock under the ATM Sales Agreement for net proceeds of $0.3 million. November 2024 Registered Direct OfferingOn November 21, 2024, the Company entered into a Securities Purchase Agreement with a single healthcare focused institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investor, 1,237,113 shares of common stock to the Investor, at a price of $2.425 per share, for aggregate gross proceeds of approximately $3.0 million before deducting the placement agents’ fees and related offering expenses.  In a concurrent private placement, the Company agreed to issue to the Investor common stock warrants to purchase up to 1,237,113 shares (the “Common Warrants”) at an exercise price of $2.95 per share, with a relative fair value of $1.1 million. Each Common Warrant will be exercisable six months from the issuance date and will expire five and one-half years from the issuance date. April